Ghaith Rabie Mohammed
College of Dentistry, University of Mosul, IraqPublications
-
Research
Comparative efficacy and safety of the BioNTech Pfizer vaccine mRNA Covid-19 vaccine, a placebo-controlled trail in Mosul city
Author(s): Ghaith Rabie Mohammed* and Ghada Younis Abdulrahman
Background: Tens of millions of individuals have been affected by a global pandemic of the coronavirus diseases 2019 (Covid-19) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We desperately needed vaccinations that are both safe and effective, as soon as possible. Methods : We randomly assigned individuals 16 years of age and older to receive one dose, two doses, or three doses 21 days apart in one arm taking the BNT162b2 vaccine candidate (30 g per dose) to be followed prospectively, and a second arm of placebo to be followed retrospectively in an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial. The SARS-CoV-2 full length spike protein is encoded by the nucleoside-modified RNA vaccine BNT162b2, which is packaged as a lipid nanoparticle. The vaccine's effectiveness against the incidence of laboratory-confirmed Covid-19 infecti.. Read More»